Compare Stocks → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BNTCNASDAQ:CYCCNASDAQ:EYEGNASDAQ:MTFBNASDAQ:TRIL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$5.25+2.3%$3.91$1.86▼$9.01$13.60M1.0215,254 shs20,970 shsCYCCCyclacel Pharmaceuticals$2.07+5.6%$2.43$1.82▼$13.20$1.74M0.56156,869 shs46,092 shsEYEGAB Corporate Bond ETF$35.75+0.1%$1.90$1.44▼$8.18$451.12M0.81935,975 shsN/AMTFBMOTIF BIO PLC/S$0.11$0.10$0.08▼$11.50N/AN/AN/A867,698 shsTRILTrillium Therapeutics$18.44$18.12$5.80▼$20.96$1.94B2.081.87 million shs8 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma+3.43%-5.87%+21.28%+55.93%+56.92%CYCCCyclacel Pharmaceuticals+2.56%-9.09%-29.82%-29.58%-76.61%EYEGAB Corporate Bond ETF+0.43%+0.71%+1.31%-0.98%+1,732.20%MTFBMOTIF BIO PLC/S0.00%0.00%0.00%0.00%0.00%TRILTrillium Therapeutics0.00%0.00%0.00%0.00%0.00%Top Project Outperforms BTC in 2023… (Ad)According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTCBenitec Biopharma2.7165 of 5 stars3.55.00.00.03.50.80.0CYCCCyclacel Pharmaceuticals2.2943 of 5 stars3.35.00.00.02.70.00.6EYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTCBenitec Biopharma3.00Buy$10.0090.48% UpsideCYCCCyclacel Pharmaceuticals2.50Moderate Buy$21.00914.49% UpsideEYEGAB Corporate Bond ETFN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest CYCC, BNTC, MTFB, TRIL, and EYEG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/15/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.001/24/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTCBenitec Biopharma$80K169.97N/AN/A$0.12 per share43.75CYCCCyclacel Pharmaceuticals$420K4.14N/AN/A$0.72 per share2.88EYEGAB Corporate Bond ETF$10K45,112.29N/AN/A$1.26 per share28.37MTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/AN/ATRILTrillium Therapeutics$150K12,907.39N/AN/A$2.56 per share7.20Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTCBenitec Biopharma-$19.56MN/A0.00∞N/AN/A-204.34%-142.81%5/20/2024 (Estimated)CYCCCyclacel Pharmaceuticals-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)EYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/AMTFBMOTIF BIO PLC/SN/AN/A0.00∞N/AN/AN/AN/AN/ATRILTrillium Therapeutics-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/ALatest CYCC, BNTC, MTFB, TRIL, and EYEG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/13/2024Q2 2024BNTCBenitec BiopharmaN/A-$2.64-$2.64-$2.64N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTCBenitec BiopharmaN/AN/AN/AN/AN/ACYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/ALatest CYCC, BNTC, MTFB, TRIL, and EYEG DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/29/2024EYEGAB Corporate Bond ETFMonthly$0.14863/1/20243/4/20243/7/20241/31/2024EYEGAB Corporate Bond ETFMonthly$0.14762/1/20242/2/20242/7/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTCBenitec Biopharma0.013.623.62CYCCCyclacel PharmaceuticalsN/A0.910.91EYEGAB Corporate Bond ETF0.013.073.07MTFBMOTIF BIO PLC/SN/AN/AN/ATRILTrillium TherapeuticsN/A19.8219.82OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTCBenitec Biopharma52.19%CYCCCyclacel Pharmaceuticals23.58%EYEGAB Corporate Bond ETF64.16%MTFBMOTIF BIO PLC/SN/ATRILTrillium Therapeutics87.15%Insider OwnershipCompanyInsider OwnershipBNTCBenitec Biopharma4.30%CYCCCyclacel Pharmaceuticals8.47%EYEGAB Corporate Bond ETF58.20%MTFBMOTIF BIO PLC/SN/ATRILTrillium Therapeutics9.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBNTCBenitec Biopharma182.59 million2.48 millionNo DataCYCCCyclacel Pharmaceuticals2,018840,000772,000OptionableEYEGAB Corporate Bond ETF1412.62 million5.28 millionNot OptionableMTFBMOTIF BIO PLC/S7N/AN/ANot OptionableTRILTrillium Therapeutics33105.00 million95.44 millionOptionableCYCC, BNTC, MTFB, TRIL, and EYEG HeadlinesSourceHeadlineCachet Bicycle shakes off COVIDbaytoday.ca - February 25 at 12:23 PMRejuvenate your look with a trip to Fourth Avenue Medical Aestheticschch.com - January 30 at 5:32 PMTTI apprehends motorists for illegal removal of clamps, hunt for four others underwaybulawayo24.com - January 30 at 5:32 PMBridgeBio raises $1.25bn, and other biotech financingspharmaphorum.com - January 19 at 7:18 AMRatio Therapeutics Raises $50M in Series B Financingprecisionmedicineonline.com - January 17 at 1:39 PMLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.combusinesswire.com - November 10 at 1:22 PMMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - November 8 at 1:30 AMThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast perioduk.finance.yahoo.com - July 31 at 9:03 AMRatio Therapeutics unveils new research and development facilitybiopharma-reporter.com - May 15 at 10:33 AMWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'msn.com - April 26 at 12:18 AMLeukemia Therapeutics Global Market Report 2023uk.finance.yahoo.com - April 4 at 10:35 AMRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merckfinance.yahoo.com - March 28 at 9:12 AMTrillium House, an affordable housing project in Warrenton, close to completiondailyastorian.com - January 10 at 12:26 AMFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinomanz.finance.yahoo.com - October 19 at 9:39 AMCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatmentseekingalpha.com - September 14 at 9:48 AMZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directorsnz.finance.yahoo.com - September 12 at 7:55 AMPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Neededseekingalpha.com - August 17 at 11:07 AMTTI reviews parking modelchronicle.co.zw - August 10 at 10:41 PMTTI working round the clock to configure its systemschronicle.co.zw - August 10 at 10:41 PMPfizer in advanced talks to buy firm making sickle cell drugspmnewsnigeria.com - August 7 at 3:57 AM10 Psychedelics CEOs To Pay Attention To In 2022markets.businessinsider.com - June 22 at 10:08 AMHighlights from ASCO Annual Meeting 2022healio.com - June 15 at 1:37 PMChlormethine gel may be more effective than ointment for mycosis fungoideshealio.com - May 27 at 4:34 PMPfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?edition.cnn.com - May 20 at 2:06 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank StocksCathie Wood Likes UiPath Stock Over NVDA, Should You?March 5, 2024 7:00 AMView Cathie Wood Likes UiPath Stock Over NVDA, Should You?Watch for Tech Giants to Boost Share Buybacks in 2024March 15, 2024 9:59 AMView Watch for Tech Giants to Boost Share Buybacks in 2024All Headlines Company DescriptionsBenitec BiopharmaNASDAQ:BNTCBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Cyclacel PharmaceuticalsNASDAQ:CYCCCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.AB Corporate Bond ETFNASDAQ:EYEGEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.MOTIF BIO PLC/SNASDAQ:MTFBMotif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.Trillium TherapeuticsNASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.